Common Stock, Value, Issued of ZyVersa Therapeutics, Inc. from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Summary
ZyVersa Therapeutics, Inc. quarterly Common Stock, Value, Issued in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • ZyVersa Therapeutics, Inc. Common Stock, Value, Issued for the quarter ending 30 Sep 2025 was $809, a 656% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Value, Issued, Quarterly (USD)
Common Stock, Value, Issued, YoY Quarterly Change (%)

ZyVersa Therapeutics, Inc. Quarterly Common Stock, Value, Issued (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $809 +$702 +656% 30 Sep 2025 10-Q 19 Nov 2025 2025 Q3
Q2 2025 $487 +$404 +487% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $257 +$174 +210% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $251 +$211 +528% 31 Dec 2024 10-Q 19 Nov 2025 2025 Q3
Q3 2024 $107 -$4,246 -98% 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $83 -$2,284 -96% 30 Jun 2024 10-Q 09 Aug 2024 2024 Q2
Q1 2024 $83 -$839 -91% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 $40 +$14 +54% 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $4,353 +$4,321 +13503% 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $2,367 +$2,335 +7297% 30 Jun 2023 10-Q 21 Aug 2023 2023 Q2
Q1 2023 $922 +$890 +2781% 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 $26 -$6 -19% 31 Dec 2022 10-K 25 Mar 2024 2023 FY
Q3 2022 $32 30 Sep 2022 10-Q 14 Nov 2022 2022 Q3
Q2 2022 $32 30 Jun 2022 10-Q 15 Aug 2022 2022 Q2
Q1 2022 $32 31 Mar 2022 10-Q 13 May 2022 2022 Q1
Q4 2021 $32 31 Dec 2021 10-Q 14 Nov 2022 2022 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.